Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4159824 | 0.88 | GPR119 (0.65) | GPR119SCN9ACHEK2 | |
| SCHEMBL4140112 | 0.85 | GPR119 (0.71) | GPR119SCN9ACHEK2DPP4 | |
| SCHEMBL20590907 | 0.83 | GPR119 (0.58) | GPR119SCN9ACHEK2FAAH | |
| SCHEMBL2158159 | 0.82 | GPR119 (0.65) | GPR119CHEK2 | |
| SCHEMBL13335340 | 0.81 | GPR119 (0.70) | GPR119CHEK2FAAH | |
| SCHEMBL1575360 | 0.81 | GPR119 (0.70) | GPR119SCN9AFAAH | |
| SCHEMBL16113557 | 0.81 | GPR119 (0.49) | GPR119SCN9ADPP4 | |
| SCHEMBL29716377 | 0.81 | GPR119 (0.63) | GPR119SCN9ACHEK2 | |
| SCHEMBL13279975 | 0.81 | GPR119 (0.63) | GPR119SCN9ACHEK2 | |
| SCHEMBL1575580 | 0.81 | GPR119 (0.68) | GPR119SCN9AFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032469-A1 | Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators | GRM2, GRM1, GRIN2B | GPR119 86/4885SCN9A 1630/4885CHEK2 4073/4885 |
| US-20080318999-A1 | Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators | GRM2, GRM1, GRIN2B | GPR119 86/4885SCN9A 1630/4885CHEK2 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.